6don MSN
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.
The rate of maternal mortality related to cardiovascular causes more than doubled between 1999 and 2022 in the United States, ...
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of ...
One study found that Black women were 3 times more likely to die of maternal deaths due to cardiovascular disease than White ...
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...
Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...
News-Medical.Net on MSN3d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...
The rate of maternal mortality related ... because heart disease and hypertension are becoming more and more prevalent, as are the conditions that are connected to heart disease, like diabetes ...
8d
March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback